GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PolyPid Ltd (NAS:PYPD) » Definitions » Notes Receivable

PYPD (PolyPid) Notes Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is PolyPid Notes Receivable?

PolyPid's Notes Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.


PolyPid Notes Receivable Historical Data

The historical data trend for PolyPid's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPid Notes Receivable Chart

PolyPid Annual Data
Trend Dec13 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PolyPid Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

PolyPid Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


PolyPid Notes Receivable Related Terms

Thank you for viewing the detailed overview of PolyPid's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


PolyPid Business Description

Traded in Other Exchanges
N/A
Address
18 Hasivim Street, P.O Box 7126, Petach Tikva, ISR, 495376
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.